Roivant and Pfizer join forces to develop TL1A drug candidate

1 December 2022

Switzerland-headquartered Roivant Sciences (Nasdaq: ROIV), a serial creator of new research-targeted start-ups, saw its share rise 7% to $5.74 by late-morning, after revealing a collaboration with US pharm giant Pfizer (NYSE: PFE) to establish a new “Vant” company.

The as-yet unnamed venture will take over a phase IIb ulcerative colitis (UC) therapy from Pfizer’s pipeline dubbed PF-06480605, which will be renamed RVT-3101. RVT-3101 is a fully human monoclonal antibody targeting TL1A, which is currently in Phase IIb development in ulcerative colitis (UC). The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase I.

Roivant plans to advance the drug for both UC and Crohn’s disease -- which represent close to a $15 billion commercial market in the USA, according to analysts at SVB Securities, who view this as a potential blockbuster dosed as a monthly subcutaneous injection with both anti-inflammatory and anti-fibrotic properties for applications in autoimmune diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK